Bulk Manufacturer of Controlled Substances Application: Siemens Healthcare Diagnostics Inc., 10534 [2019-05392]
Download as PDF
<![CDATA[
amozie on DSK9F9SC42PROD with NOTICES
10534
Federal Register / Vol. 84, No. 55 / Thursday, March 21, 2019 / Notices
file written submissions on the issues of
remedy, the public interest, and
bonding. Third-party submissions
should be filed no later than the close
of business on March 29, 2019. No
further submissions on any of these
issues will be permitted unless
otherwise ordered by the Commission.
Persons filing written submissions
must file the original document
electronically on or before the deadlines
stated above and submit eight (8) true
paper copies to the Office of the
Secretary by noon the next day,
pursuant to section 201.4(f) of the
Commission’s Rule of Practice and
Procedure (19 CFR 210.4(f)).
Submissions should refer to the
investigation number (‘‘Inv. No. 337–
TA–1076’’) in a prominent place on the
cover page and/or first page. (See
Handbook for Electronic Filing
Procedures, https://www.usitc.gov/
documents/handbook_on_filing_
procedures.pdf). Persons with questions
regarding filing should contact the
Secretary (202–205–2000).
Any person desiring to submit a
document to the Commission in
confidence must request confidential
treatment. All such requests should be
directed to the Secretary to the
Commission and include a full
statement of the reasons why the
Commission should grant such
treatment. See 19 CFR 201.6. Documents
for which confidential treatment by the
Commission is properly sought will be
treated accordingly. All information,
including confidential business
information and documents for which
confidential treatment is properly
sought, submitted to the Commission for
purposes of this Investigation may be
disclosed to and used: (i) By the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
and evaluations relating to the
programs, personnel, and operations of
the Commission including under 5
U.S.C. Appendix 3; or (ii) by U.S.
government employees and contract
personnel[1] solely for cybersecurity
purposes. All non-confidential written
submissions will be available for public
inspection at the Office of the Secretary
and on EDIS.
The authority for the Commission’s
determination is contained in Section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in part
210 of the Commission’s Rules of
1 All contract personnel will sign appropriate
nondisclosure agreements.
VerDate Sep<11>2014
18:27 Mar 20, 2019
Jkt 247001
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: March 15, 2019.
Katherine Hiner,
Acting Secretary to the Commission.
[FR Doc. 2019–05353 Filed 3–20–19; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Siemens
Healthcare Diagnostics Inc.
ACTION:
JOINT BOARD FOR THE
ENROLLMENT OF ACTUARIES
Meeting of the Advisory Committee;
Meeting
Joint Board for the Enrollment
of Actuaries.
ACTION: Notice of Federal Advisory
Committee meeting.
AGENCY:
The Joint Board for the
Enrollment of Actuaries gives notice of
a closed meeting of the Advisory
Committee on Actuarial Examinations.
DATES: The meeting will be held on
April 12, 2019, from 8:30 a.m. to 5:00
p.m.
ADDRESSES: The meeting will be held at
Willis Towers Watson, 500 N Akard
Street, 41st Floor, Dallas, TX 75201.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Van Osten, Designated Federal
Officer, Advisory Committee on
Actuarial Examinations, at (202) 317–
3648.
SUMMARY:
Notice is
hereby given that the Advisory
Committee on Actuarial Examinations
will meet at Willis Towers Watson, 500
N Akard Street, 41st Floor, Dallas, TX
75201, on April 12, 2019, from 8:30 a.m.
to 5:00 p.m.
The purpose of the meeting is to
discuss topics and questions that may
be recommended for inclusion on future
Joint Board examinations in actuarial
mathematics, pension law and
methodology referred to in 29 U.S.C.
1242(a)(1)(B).
A determination has been made as
required by section 10(d) of the Federal
Advisory Committee Act, 5 U.S.C. App.,
that the subject of the meeting falls
within the exception to the open
meeting requirement set forth in Title 5
U.S.C. 552b(c)(9)(B), and that the public
interest requires that such meeting be
closed to public participation.
SUPPLEMENTARY INFORMATION:
Dated: March 14, 2019.
Thomas V. Curtin, Jr.,
Executive Director, Joint Board for the
Enrollment of Actuaries.
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before May 20, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on Dec 12,
2018, Siemens Healthcare Diagnostics
Inc., 100 GBC Drive, Mailstop 514,
Newark, Delaware 19702–2461 applied
to be registered as a bulk manufacturer
of the following basic class of controlled
substance:
SUPPLEMENTARY INFORMATION:
Controlled substance
Ecgonine ........................
Drug
code
9180
Schedule
II
The company plans to produce the
listed controlled substance in bulk to be
used in the manufacture of DEA exempt
products.
Dated: March 6, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–05402 Filed 3–20–19; 8:45 am]
[FR Doc. 2019–05392 Filed 3–20–19; 8:45 am]
BILLING CODE 4830–01–P
BILLING CODE 4410–09–P
PO 00000
Frm 00059
Fmt 4703
Sfmt 9990
E:\FR\FM\21MRN1.SGM
21MRN1
]]>Agencies
[Federal Register Volume 84, Number 55 (Thursday, March 21, 2019)]
[Notices]
[Page 10534]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-05392]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Siemens
Healthcare Diagnostics Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before May 20, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on Dec
12, 2018, Siemens Healthcare Diagnostics Inc., 100 GBC Drive, Mailstop
514, Newark, Delaware 19702-2461 applied to be registered as a bulk
manufacturer of the following basic class of controlled substance:
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Ecgonine............................... 9180 II
------------------------------------------------------------------------
The company plans to produce the listed controlled substance in
bulk to be used in the manufacture of DEA exempt products.
Dated: March 6, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-05392 Filed 3-20-19; 8:45 am]
BILLING CODE 4410-09-P
